Middle Molecule Find

Rulebook › V-tags › V382

V382 Evaluation after reactions, and suspending reuse

Written V0382 on the CMS-2567 and in QCOR.

Enforces 42 CFR 494.50(c)(2)(ii) · Appendix H Rev. 246, page 185 · checked 12 Nov 2026

Cited on this tag? What happens after a citation · One-page sheet for the binder

The regulation

§ 494.50(c)(2) – When clinically indicated (for example, after adverse patient reactions), the facility must – (ii) Undertake evaluation of its dialyzer reprocessing and water purification system. When this evaluation suggests a cluster of adverse patient reactions is associated with hemodialyzer reuse, the facility must suspend reuse of hemodialyzers until it is satisfied the problem has been corrected.

Read 42 CFR 494.50 on the eCFR

CMS's interpretive guidance

Interpretive Guidance § 494.50(c)(2)(ii)

In this context, “cluster” refers to a group of hemodialysis patients suspected of having adverse reactions that could be clinically related to dialyzer reprocessing and/or reuse practices.

Responsible staff (e.g., chief technician, area technical manager, medical director) must be able to describe actions to be taken if a group of patients experiences adverse reactions potentially related to reprocessing/reuse. If a cluster of adverse patient reactions associated with reprocessing/reuse was identified, dialyzer reprocessing/reuse should be suspended, pending investigation.

Verbatim from Appendix H Rev. 246, with CMS's headings, lists and bold. Check page 185 (the full 469-page PDF) before quoting it.